Novel approach to increase efficacy and safety of marketed Alzheimer's drugs
Total raised: $21M
Investors 1
| Date | Name | Website |
| - | Andera Par... | anderapart... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.05.2014 | Series B | $21M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 20.01.2018 | Cipla invests additional $3 mn in US’ Chase Pharmaceuticals... | Drug firm Cipla Ltd has made an additional investment of $3 million in the US-based Chase Pharmaceut... | thehindubu... |
| 28.03.2016 | Former Allergan president’s new venture, Chase Pharmaceutica... | Alzheimer’s disease has been notoriously difficult treat, as the biological underpinnings have yet t... | medcitynew... |
| 12.05.2014 | Chase Pharmaceuticals Raises $21M in Series B | WASHINGTON, DC, Chase Pharmaceuticals Corporation today announced a $21 million Series B financing... | vcnewsdail... |
| 12.05.2014 | Chase Pharmaceuticals Raises $21M in Series B Financing | Chase Pharmaceuticals, a Washington, DC-based early stage drug development company, raised $21m in S... | finsmes.co... |
| - | Former Allergan president’s new venture, Chase Pharmaceutica... | Soon after appointing former Allergan president Doug S. Ingram as its chief executive, Chase Pharmac... | medcitynew... |